Septerna (SEPN) Form 4: SVP Uwe Klein 30,000 Options at $11.70

Septerna, Inc. reporting person Uwe Klein, SVP, Biological Sciences, reported acquisition on Form 4 of 30,000 stock options on 08/07/2025.

Rhea-AI Filing Summary

Septerna, Inc. reporting person Uwe Klein, SVP, Biological Sciences, reported acquisition on Form 4 of 30,000 stock options on 08/07/2025. The options carry an exercise price of $11.70 and relate to 30,000 shares of common stock; they are shown as directly owned. The options are listed as exercisable beginning 08/06/2025 and subject to a vesting schedule where 1/48th of the shares vest in substantially equal monthly installments starting August 1, 2025, contingent on the reporting person's continuous service. The form was signed by attorney-in-fact Ran Xiao on 08/11/2025.

Insights

Financial Analyst

TL;DR: Insider option grant of 30,000 shares to SVP Uwe Klein; routine compensation disclosure.

The filing documents an acquisition of 30,000 stock options with an exercise price of $11.70, reported as a direct holding. The options are shown as exercisable beginning 08/06/2025 and carry a defined vesting schedule of 1/48th per month starting 08/01/2025, subject to continuous service. This is a standard Form 4 disclosure of an officer award rather than an exercise or sale; the form was executed by an attorney-in-fact on 08/11/2025.

Corporate Governance Expert

TL;DR: Grant follows a time-based vesting schedule; disclosure aligns with Section 16 reporting requirements.

The report identifies Uwe Klein as an officer (SVP, Biological Sciences) receiving 30,000 options, directly owned, with explicit vesting terms (1/48th monthly beginning 08/01/2025). The filing includes transaction date 08/07/2025 and signature by an attorney-in-fact on 08/11/2025. From a governance standpoint, the document records standard insider compensation mechanics and required Section 16 reporting; it does not show exercises, dispositions, or other transfers.

Insider Trade Summary

Grant/Award: 30,000 shares

Grant/Award 1 txn

Insider Klein Uwe

Role SVP, Biological Sciences

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	30,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 30,000 contracts (Direct)

Footnotes (1)

1. F1. 1/48th of the shares subject to such option shall vest and become exercisable in substantially equal monthly installments on each monthly anniversary of August 1, 2025, subject to the Reporting Person's continuous service to the Issuer on each such date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What transaction did Uwe Klein report on the SEPN Form 4?

The Form 4 reports acquisition of 30,000 stock options on 08/07/2025 with an exercise price of $11.70.

What is Uwe Klein's relationship to Septerna (SEPN)?

The filing lists Uwe Klein as an Officer, titled SVP, Biological Sciences.

When are the options exercisable and what is the vesting schedule?

Options are shown as exercisable beginning 08/06/2025 and vesting at 1/48th of the shares monthly starting 08/01/2025, subject to continuous service.

How many underlying shares are covered by the derivative security reported for SEPN?

The derivative security relates to 30,000 shares of common stock underlying the stock option.

Who signed the Form 4 for SEPN and when?

The Form 4 was signed by attorney-in-fact Ran Xiao on 08/11/2025.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 08/11/2025 - 07:01 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Klein Uwe

(Last) (First) (Middle)

C/O SEPTERNA, INC.

250 EAST GRAND AVENUE

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Septerna, Inc. [ SEPN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, Biological Sciences

3. Date of Earliest Transaction (Month/Day/Year)
08/07/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$11.7	08/07/2025		A		30,000		(1)	08/06/2025	Common Stock	30,000	$0	30,000	D

Explanation of Responses:

1. 1/48th of the shares subject to such option shall vest and become exercisable in substantially equal monthly installments on each monthly anniversary of August 1, 2025, subject to the Reporting Person's continuous service to the Issuer on each such date.

	/s/ Ran Xiao, Attorney-in-Fact	08/11/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.